{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:03:18Z","timestamp":1792342998407,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1124\/jpet.119.258343","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T18:45:12Z","timestamp":1562179512000},"page":"447-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E\u2013Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators"],"prefix":"10.1016","volume":"370","author":[{"given":"Robyn","family":"Bruen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se\u00e1n","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Kajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella E.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne T.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-3503","authenticated-orcid":false,"given":"Fiona C.","family":"McGillicuddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7701-6540","authenticated-orcid":false,"given":"Orina","family":"Belton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.258343_bib1","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"10.1124\/jpet.119.258343_bib2","doi-asserted-by":"crossref","first-page":"e0168396","DOI":"10.1371\/journal.pone.0168396","article-title":"Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr\u2212\/\u2212 mice","volume":"11","author":"Bisgaard","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.258343_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cmet.2011.07.015","article-title":"Insulin resistance, hyperglycemia, and atherosclerosis","volume":"14","author":"Bornfeldt","year":"2011","journal-title":"Cell Metab"},{"key":"10.1124\/jpet.119.258343_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2017101112","article-title":"Lipoxins regulate the early growth response-1 network and reverse diabetic kidney disease","volume":"29","author":"Brennan","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.119.258343_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12933-017-0626-3","article-title":"Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","volume":"16","author":"Bruen","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/jpet.119.258343_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12950-015-0060-9","article-title":"Conjugated linoleic acid induces an atheroprotective macrophage M\u03a62 phenotype and limits foam cell formation","volume":"12","author":"de Gaetano","year":"2015","journal-title":"J Inflamm (Lond)"},{"key":"10.1124\/jpet.119.258343_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fimmu.2016.00275","article-title":"M1- and M2-type macrophage responses are predictive of adverse outcomes in human atherosclerosis","volume":"7","author":"de Gaetano","year":"2016","journal-title":"Front Immunol"},{"key":"10.1124\/jpet.119.258343_bib8","doi-asserted-by":"crossref","first-page":"e0120633","DOI":"10.1371\/journal.pone.0120633","article-title":"Serum levels of monocyte chemoattractant protein-1 and all-cause and cardiovascular mortality among patients with coronary artery disease","volume":"10","author":"Ding","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.258343_bib9","first-page":"1","article-title":"A human ex vivo atherosclerotic plaque model to study lesion biology","volume":"87","author":"Erbel","year":"2014","journal-title":"J Vis Exp"},{"key":"10.1124\/jpet.119.258343_bib10","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1007\/s00125-013-2918-9","article-title":"An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy","volume":"56","author":"Fadini","year":"2013","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.119.258343_bib11","doi-asserted-by":"crossref","first-page":"e39790","DOI":"10.1371\/journal.pone.0039790","article-title":"Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome","volume":"7","author":"Feig","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.258343_bib12","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.2337\/db08-1475","article-title":"Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice","volume":"58","author":"Fujisaka","year":"2009","journal-title":"Diabetes"},{"key":"10.1124\/jpet.119.258343_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1479164111404257","article-title":"A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-\/- mouse model","volume":"8","author":"Gaspari","year":"2011","journal-title":"Diab Vasc Dis Res"},{"key":"10.1124\/jpet.119.258343_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/1479164113481817","article-title":"The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-\/-) mouse model","volume":"10","author":"Gaspari","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1124\/jpet.119.258343_bib15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00041433-199910000-00006","article-title":"Homocysteine and atherosclerosis","volume":"10","author":"Gerhard","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1124\/jpet.119.258343_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.119.258343_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"10.1124\/jpet.119.258343_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.119.258343_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1096\/fj.12-215442","article-title":"IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis","volume":"27","author":"McCarthy","year":"2013","journal-title":"FASEB J"},{"key":"10.1124\/jpet.119.258343_bib20","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.119.258343_bib21","first-page":"192","article-title":"Proinflammatory monocyte polarization in type 2 diabetes mellitus and coronary heart disease","volume":"1","author":"Nikiforov","year":"2017","journal-title":"Vessel Plus"},{"key":"10.1124\/jpet.119.258343_bib22","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.115.020278","article-title":"High-density lipoprotein proteomic composition, and not efflux capacity, reflects differential modulation of reverse cholesterol transport by saturated and monounsaturated fat diets","volume":"133","author":"O\u2019Reilly","year":"2016","journal-title":"Circulation"},{"key":"10.1124\/jpet.119.258343_bib23","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.20170355","article-title":"The fate and lifespan of human monocyte subsets in steady state and systemic inflammation","volume":"214","author":"Patel","year":"2017","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.119.258343_bib24","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1172\/JCI75005","article-title":"Inflammatory Ly6Chi monocytes and their conversion to M2 macrophages drive atherosclerosis regression","volume":"127","author":"Rahman","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.119.258343_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1210\/jc.2014-2291","article-title":"Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study","volume":"100","author":"Rizzo","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.119.258343_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/362801a0","article-title":"The pathogenesis of atherosclerosis: a perspective for the 1990s","volume":"362","author":"Ross","year":"1993","journal-title":"Nature"},{"key":"10.1124\/jpet.119.258343_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.119.258343_bib28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.immuni.2017.09.008","article-title":"Monocyte-macrophages and T cells in atherosclerosis","volume":"47","author":"Tabas","year":"2017","journal-title":"Immunity"},{"key":"10.1124\/jpet.119.258343_bib29","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Vinu\u00e9","year":"2017","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.119.258343_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lfs.2016.09.025","article-title":"Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance","volume":"166","author":"Ye","year":"2016","journal-title":"Life Sci"},{"key":"10.1124\/jpet.119.258343_bib31","first-page":"163","article-title":"The function of cathepsins B, D, and X in atherosclerosis","volume":"6","author":"Zhao","year":"2016","journal-title":"Am J Cardiovasc Dis"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524260663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.258343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:54:21Z","timestamp":1739976861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524260663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0022356524260663"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.258343","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E\u2013Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.258343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}